Mark W. Schwartz, Ph.D. has served as our President & Chief Executive Officer since March 2004. From 2003 to 2004, Dr. Schwartz was Managing Director of Life Sciences at Arizona Technology Enterprises. From 2001 to 2003, Dr. Schwartz was Chief Executive Officer and President of Calyx Therapeutics Inc. From 1999 to 2001, Dr. Schwartz was Chief Commercial Officer of Trega BioSciences, Inc. From 1997 to 1998, Dr. Schwartz held senior management positions at Synteni, Inc. and Incyte Genomics, Inc., which acquired Synteni, Inc. in 1998. From 1994 to 1997, Dr. Schwartz held senior management positions at Tripos, Inc. From 1989 to 1994, Dr. Schwartz held marketing positions at Biosym Technologies, Inc., which was acquired by Corning Incorporated in 1992, and Applied Biosystems Inc. From 1983 to 1989 Dr. Schwartz held research and development as well as marketing positions in the diagnostics business of E.I. du Pont de Nemours and Company. Dr. Schwartz received a B.A. in Chemistry from Grinnell College and a Ph.D. in Biochemistry from Arizona State University.



Fred Kurland has served as our Chief Financial Officer since May 2007. From 2004 to 2007, Mr. Kurland was Chief Financial Officer of Corcept Therapeutics Incorporated. From 2002 to 2004, Mr. Kurland was Vice President, Chief Financial Officer of Genitope Corporation. From 1998 to 2002, Mr. Kurland was Senior Vice President and Chief Financial Officer of Aviron, which was acquired by MedImmune, Inc. in 2002. From 1996 to 1998, he was Vice President and Chief Financial Officer of Protein Design Labs, Inc. From 1995 to 1996, Mr. Kurland was Vice President and Chief Financial Officer of Applied Immune Sciences, Inc. He held a number of financial management positions at Syntex Corporation between 1981 and 1995, including Vice President and Controller between 1991 and 1995. Mr. Kurland received a B.S. in Business and Economics from Lehigh University and an M.B.A. and a J.D. from the University of Chicago.



Frank H. Valone, M.D. has served as our Senior Vice President of Medical Affairs since November 2003. From 2002 to 2003, Dr. Valone was Executive Vice President, Clinical Development and Regulatory Affairs of Titan Pharmaceuticals, Inc. From 1994 to 2002, Dr. Valone was Senior Vice President, Medical and Regulatory Affairs at Dendreon Corporation. From 1991 to 1996, he held various positions at Dartmouth-Hitchcock Medical Center, including Adjunct Professor of Medicine, and from 1982 to 1991, he held various positions at the University of California in San Francisco, including Associate Professor of Medicine. From 1995 to 2001, he was a Clinical Associate Professor in the Department of Medicine at Stanford University. Dr. Valone received a B.A. from Hamilton College and an M.D. from Harvard Medical School.



Hideki Garren, M.D., Ph.D. co-founded Bayhill in 2001 and has served as our Vice President of Research since 2005, and prior to that served as our Director of Research from 2001 to 2005. Since 2003, Dr. Garren has been a member of the adjunct clinical faculty in the Department of Neurology at Stanford University School of Medicine. Dr. Garren received a B.S. from the California Institute of Technology, a Ph.D. in Molecular Biology from the University of California, Los Angeles, Molecular Biology Institute, and an M.D. from the University of California, Los Angeles, School of Medicine.



Robert S. King, Ph.D. has served as our Vice President of Manufacturing since October 2006. From 2004 to 2006, he was Vice President of Product Development and Manufacturing at Rinat Neuroscience Corporation, a division of Pfizer Global Research and Development from 2006 to present. From 1993 to 2003, Dr. King served in a series of positions of increasing responsibility in the areas of Process and Product Development, Manufacturing and Technical Operations at Millennium Pharmaceuticals, Inc.’s South San Francisco office and COR Therapeutics, Inc., which merged with Millennium Pharmaceuticals, Inc. in 2002. From 1991 to 1993, Dr. King served in various pharmaceutical and process research roles of increasing responsibility at Scios, Inc., formerly California Biotechnology, Inc. From 1988 to 1991, he served in various device development and sales/marketing roles of increasing responsibility at Molecular Devices Corp. Dr. King was also an adjunct professor in Chemical Engineering at San Jose State University from 1991 to 1992 and served on the Advisory Board for the San Jose State Masters in Biotechnology program from 2003 to 2005. Dr. King received a B.S. in Chemical Engineering from the University of Washington, Seattle and a Ph.D. in Chemical Engineering from the University of California, Berkeley.



Patricia A. Murphy has served as our Vice President Regulatory Affairs since January 2005. From 1996 to 2004, Ms. Murphy was Director Regulatory Affairs and Quality Assurance at Berlex Laboratories. From 1993 to 1996, Ms. Murphy was a senior regulatory affairs specialist at Serono Laboratories Inc. From 1991 to 1993, Ms. Murphy was a regulatory affairs specialist at Parexel International Corporation. From 1988 to 1991, Ms. Murphy was a manufacturing supervisor at Biogen, Inc., responsible for manufacturing clinical trial material. Ms. Murphy received a B.Sc. in Biochemistry from Worcester Polytechnic Institute.



Paul B. Westberg has served as our Vice President of Business Development since November 2006. From 2002 to 2006, Mr. Westberg was Vice President of Business Development at Novacea, Inc. Mr. Westberg held managerial positions at Deltagen, Inc. from 2001 to 2002, Collabra Pharma, Inc. from 2000 to 2001, and Aviron in 1999. From 1996 to 1999, Mr. Westberg served in various positions at Genentech, Inc., including Manager, Project Finance and Manager, Financial Planning and Analysis. Mr. Westberg received a B.A. in Applied Mathematics from the University of California, San Diego and an M.B.A. from the University of California, Berkeley.